COVID-19 Therapeutics I: Clinical development of our targeted SARS-CoV-2 helicase inhibitor EIS-10700 - inhibition of viral replication for COVID-19 therapy (EisCor_2)
- Funded by Federal Ministry of Research, Technology and Space (BMFTR)
- Total publications:0 publications
Grant number: 03LW0012
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$5,292,861.5Funder
Federal Ministry of Research, Technology and Space (BMFTR)Research Location
GermanyLead Research Institution
Eisbach Bio GmbHResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
N/ASpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
N/A